Insider at Aura Biosciences (AURA) files to sell 16,928 shares after prior sale

Rhea-AI Filing Summary

Aura Biosciences insider Elisabet de los Pinos has filed a Rule 144 notice to sell 16,928 shares of common stock through Morgan Stanley Smith Barney LLC on or about 01/20/2026, with an indicated aggregate market value of $82,234.36 on Nasdaq. These shares relate to a restricted stock unit award of 30,469 shares granted on 01/19/2023 under the company’s 2021 Stock Option and Incentive Plan. The notice also discloses that 9,049 shares of common stock were sold in the past three months for $57,461.15. Aura Biosciences had 63,503,269 shares of common stock outstanding, providing scale for the planned sale.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Drive 200 West Civic Center 4th Floor Sandy UT 84070	16928	82234.36	63503269	01/20/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/19/2023	Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements.	Aura Biosciences, Inc.			30469	01/19/2023	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Elisabet de los Pinos 80 Guest Street Boston MA 02135	Common Stock	10/29/2025	9049	57461.15

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for AURA disclose?

The Form 144 discloses that an Aura Biosciences insider, Elisabet de los Pinos, intends to sell 16,928 shares of the company’s common stock under Rule 144 through Morgan Stanley Smith Barney LLC, with an approximate sale date of 01/20/2026 on Nasdaq.

How many Aura Biosciences (AURA) shares are planned to be sold under this Form 144?

The notice covers a planned sale of 16,928 shares of Aura Biosciences common stock, with an indicated aggregate market value of $82,234.36.

How were the Aura Biosciences (AURA) shares being sold acquired?

The shares were acquired via a restricted stock unit award of 30,469 shares granted on 01/19/2023 under Aura Biosciences’ 2021 Stock Option and Incentive Plan, subject to vesting requirements.

Has the Aura Biosciences insider sold any shares recently before this Form 144?

Yes. The filing states that 9,049 shares of Aura Biosciences common stock were sold on 10/29/2025, generating $57,461.15 in gross proceeds.

How many Aura Biosciences (AURA) shares are outstanding according to the Form 144?

The Form 144 indicates that there are 63,503,269 shares of Aura Biosciences common stock outstanding, which provides context for the size of the planned sale.

Which broker will handle the planned Aura Biosciences (AURA) share sale?

The planned sale of 16,928 shares is to be executed through Morgan Stanley Smith Barney LLC, based in Sandy, Utah.